MarketCapExport financials
Aziyo Biologics (AZYO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Aziyo Biologics Income Statement 2025-2011 | AZYO
Brief overview of financial performance at Aziyo Biologics
The conclusions below are based on five years of reported results. Revenue at Aziyo Biologics moved from $42.7 million in 2020 to $12.3 million in 2025. Across the full period, sales moved by −71.2%; the average annual rate was −22%. Sales followed a declining trajectory over the five years.
The gross result shifted from 20.6 million dollars to 6.6 million dollars, or −67.9%. Revenue and direct costs changed at similar rates. The gross margin was 48.2% at the start and 53.7% at the end. The expansion indicates stronger pricing power or better control of direct costs.
EBITDA changed from −9.7 million dollars to −24.1 million dollars (−147.8%). The operating result developed less favorably than sales. Comparing the endpoints gives EBITDA margins of −22.8% and −196.3%. Operating return per unit of revenue declined.
The final result was −$21.8 million initially and $53.4 million in the final year. The company restored profitability by the end of the period.
What the figures show
The financial trajectory is weak and requires a cautious interpretation. The strongest signals are a stronger final result and improving gross profitability. The most visible risks are pressure on operating profitability, a low EBITDA margin and a softer top-line trend. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Aziyo Biologics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | - | 26.9 M | 56.7 M | 65.8 M | 165 M | - | - | - | - | - | - | - | - | - |
Shares |
41.4 M | 29.1 M | 18.2 M | 13.8 M | 10.4 M | 10.2 M | - | - | - | - | - | - | - | - | - |
Historical Prices |
- | - | 1.48 | 4.1 | 6.3 | 13.6 | - | - | - | - | - | - | - | - | - |
Net Income |
53.4 M | -53.9 M | -37.7 M | -32.9 M | -24.8 M | -21.8 M | -11.9 M | -11.6 M | - | - | - | - | - | - | - |
Revenue |
12.3 M | 14.5 M | 24.7 M | 23.8 M | 47.4 M | 42.7 M | 42.9 M | 39 M | - | - | - | - | - | - | - |
Cost of Revenue |
5.7 M | 7.75 M | 13.7 M | 12.2 M | 28.4 M | 22.1 M | 23.1 M | - | - | - | - | - | - | - | - |
Gross Profit |
6.6 M | 6.72 M | 11.1 M | 11.6 M | 19 M | 20.6 M | 19.8 M | 15.9 M | - | - | - | - | - | - | - |
Operating Income |
-26.9 M | -30.7 M | -30.5 M | -35.2 M | -23 M | -13.6 M | -8.41 M | - | - | - | - | - | - | - | - |
Interest Expense |
-2.76 M | 1.19 M | 5.8 M | 5.12 M | 5.32 M | 5.63 M | 5.38 M | - | - | - | - | - | - | - | - |
EBITDA |
-24.1 M | -27.3 M | -26.8 M | -31.5 M | -19.3 M | -9.74 M | -4.55 M | -4.4 M | - | - | - | - | - | - | - |
Operating Expenses |
33.5 M | 37.4 M | 41.6 M | 46.8 M | 42.1 M | 34.2 M | 28.2 M | 24.2 M | - | - | - | - | - | - | - |
General and Administrative Expenses |
15.1 M | 18.1 M | 14.1 M | 16.1 M | 13.7 M | 13.2 M | 9.62 M | 8.52 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Aziyo Biologics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
43 M | 42.4 M | 41.8 M | 38.6 M | 32.5 M | 24.9 M | 23.9 M | 17 M | 16.2 M | 16.1 M | - | 13.7 M | 13.6 M | 13.6 M | - | 10.2 M | 10.2 M | 10.2 M | - | 648 K | 648 K | 648 K | 648 K | 645 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-7.47 M | -3.87 M | -9.61 M | -3.93 M | 1.29 M | -28.2 M | -18 M | -9.75 M | -10.6 M | -7.97 M | - | -9.91 M | -9.4 M | -8.15 M | - | -8.32 M | -2.38 M | -5.07 M | - | -6.73 M | -5.18 M | -4.56 M | - | -3.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
3.11 M | 3.32 M | 6.26 M | 6.03 M | 3.66 M | 6.29 M | 6.69 M | 6.13 M | 6.35 M | 6.39 M | - | 5.85 M | 12.6 M | 11.5 M | - | 11.5 M | 12.2 M | 12.9 M | - | 11.8 M | 8.58 M | 9.86 M | - | 11.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
1.31 M | 1.47 M | 3.2 M | 3.57 M | 1.87 M | 3.49 M | 3.85 M | 3.29 M | 3.64 M | 3.02 M | - | 2.91 M | 7.74 M | 7.21 M | - | 7.8 M | 6.55 M | 6.56 M | - | 6.23 M | 4.8 M | 4.65 M | - | 5.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
1.8 M | 1.85 M | 3.06 M | 2.46 M | 1.79 M | 2.8 M | 2.84 M | 2.84 M | 2.71 M | 3.37 M | - | 2.94 M | 4.9 M | 4.28 M | - | 3.69 M | 5.61 M | 6.33 M | - | 5.54 M | 3.78 M | 5.22 M | - | 5.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-6.35 M | -5.21 M | -9.88 M | -7.92 M | -9.18 M | -8.51 M | -8.48 M | -7.37 M | -6.31 M | -8.34 M | - | -8.97 M | -8.18 M | -6.92 M | - | -6.98 M | -4.6 M | -3.7 M | - | -2.69 M | -3.76 M | -3.18 M | - | -1.85 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
71 K | - | -1.44 M | -105 K | - | -257 K | 1.44 M | -758 K | 1.52 M | 1.43 M | - | 1.25 M | 1.2 M | 1.22 M | - | 1.33 M | 1.35 M | 1.36 M | - | 1.46 M | 1.41 M | 1.37 M | - | 1.25 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-6.02 M | - | - | -7.05 M | -8.33 M | -7.66 M | -7.62 M | -6.52 M | -5.46 M | -7.39 M | - | -8.12 M | -7.33 M | -5.99 M | - | -4.18 M | -2.73 M | -2.77 M | - | 230 K | -1.81 M | -2.21 M | - | 1.04 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
8.15 M | 7.06 M | 12.9 M | 10.4 M | 11 M | 11.3 M | 11.3 M | 10.2 M | 9.02 M | 11.7 M | - | 11.9 M | 13.1 M | 11.2 M | - | 10.7 M | 10.2 M | 10 M | - | 8.23 M | 7.55 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
4.09 M | 3.52 M | 3.7 M | 3.87 M | 4.34 M | 4.69 M | 5.06 M | 2.76 M | 3.86 M | 3.52 M | - | 4.33 M | 4.71 M | 4.02 M | - | 3.52 M | 3.53 M | 3.6 M | - | 2.67 M | 2.08 M | 2.61 M | - | 2.45 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Aziyo Biologics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Israel
France
Britain
